Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 4/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.50 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.50 |
| ▸ | CCR2 | P41597 | 2/20 | 0.49 |
| ▸ | GSK3B | P49841 | 2/20 | 0.47 |
| ▸ | CHRM4 | P08173 | 5/20 | 0.47 |
| ▸ | DRD2 | P14416 | 3/20 | 0.46 |
| ▸ | DRD4 | P21917 | 3/20 | 0.46 |
| ▸ | DRD3 | P35462 | 2/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.45 |
| ▸ | CACNA1I | Q9P0X4 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7254158 | 0.96 | HTR4 (0.51) | HTR4CHRM2CHRM1CHRM5CHRM3 | |
| SCHEMBL6336300 | 0.89 | CCR2 (0.59) | HTR4CCR2GSK3BCHRM4DRD2 | |
| SCHEMBL6329186 | 0.88 | HTR4 (0.66) | HTR4CCR2DRD2DRD4DRD3 | |
| SCHEMBL6329068 | 0.88 | HTR4 (0.56) | HTR4CCR2DRD2DRD4DRD3 | |
| SCHEMBL6331358 | 0.87 | HTR4 (0.58) | HTR4CHRM4DRD2DRD4DRD3 | |
| SCHEMBL6331337 | 0.86 | HTR4 (0.50) | HTR4CHRM2CHRM1CHRM5CHRM3 | |
| SCHEMBL6336876 | 0.86 | HTR4 (0.54) | HTR4CCR2DRD2DRD4DRD3 | |
| SCHEMBL6329791 | 0.86 | KCNH2 (0.61) | HTR4CCR2DRD2DRD4DRD3 | |
| SCHEMBL6329269 | 0.86 | DRD2 (0.58) | HTR4DRD2DRD4DRD3 | |
| SCHEMBL6331374 | 0.86 | HTR4 (0.56) | HTR4CCR2GSK3BDRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6979690-B2 | Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators | PFIZER INC. (US) | 2005-12-27 | — | — | US | claimed |
| US-20030207875-A1 | Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators | PFIZER INC | 2003-11-06 | — | — | US | claimed |
| EP-1325921-A2 | Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators | Pfizer Inc. (US) | 2003-07-09 | — | — | EP | claimed |
| US-6979690-B2 | Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators | PFIZER INC. (US) | 2005-12-27 | — | — | US | disclosed |
| US-20030207875-A1 | Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators | PFIZER INC | 2003-11-06 | — | — | US | disclosed |
| JP-2003212868-A | OXO- OR OXY-PYRIDINE AS 5-HT4 RECEPTOR MODULATOR | PFIZER PHARMACEUTICALS INC | 2003-07-30 | — | — | JP | disclosed |
| EP-1325921-A2 | Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators | Pfizer Inc. (US) | 2003-07-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207875-A1 | Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators | HRH4, HRH2, HTR4 | HTR4 3/4885CHRM2 254/4885CHRM1 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.